EA202090005A1 - Антитела, модулирующие биологическую активность, проявляемую клеткой - Google Patents

Антитела, модулирующие биологическую активность, проявляемую клеткой

Info

Publication number
EA202090005A1
EA202090005A1 EA202090005A EA202090005A EA202090005A1 EA 202090005 A1 EA202090005 A1 EA 202090005A1 EA 202090005 A EA202090005 A EA 202090005A EA 202090005 A EA202090005 A EA 202090005A EA 202090005 A1 EA202090005 A1 EA 202090005A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lag
cell
bind
variable domain
biological activity
Prior art date
Application number
EA202090005A
Other languages
English (en)
Inventor
Сесилия Анна Вильгельмина Гёин
Ринсе Клостер
Корнелис Адриан Де Крёйф
Паулус Йоханнес Таккен
Марк Тросби
Тон Логтенберг
Original Assignee
Мерус Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерус Н.В. filed Critical Мерус Н.В.
Publication of EA202090005A1 publication Critical patent/EA202090005A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

Изобретение обеспечивает средства и способы препятствования опосредуемому белком запрограммированной гибели клеток 1 (Programmed Cell Death 1 белок (PD-1)) и активатором лимфоцитов 3 (LAG-3), ингибированию в PD-1-положительной и/или LAG-3-положительной клетке. Способ может включать приведение указанной клетки в контакт с антителом или его функциональной частью, производным и/или аналогом, содержащими вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью LAG-3, тем самым ингибируя опосредуемую PD-1 и/или LAG-3 активность в указанной клетке. Изобретение также обеспечивает антитела или их варианты, содержащие вариабельный домен, который может связываться с внеклеточной частью PD-1, и вариабельный домен, который может связываться с внеклеточной частью LAG-3.
EA202090005A 2017-07-06 2018-07-06 Антитела, модулирующие биологическую активность, проявляемую клеткой EA202090005A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17180070 2017-07-06
PCT/NL2018/050451 WO2019009728A1 (en) 2017-07-06 2018-07-06 ANTIBODIES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL

Publications (1)

Publication Number Publication Date
EA202090005A1 true EA202090005A1 (ru) 2020-06-18

Family

ID=59295099

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090005A EA202090005A1 (ru) 2017-07-06 2018-07-06 Антитела, модулирующие биологическую активность, проявляемую клеткой

Country Status (14)

Country Link
US (2) US11732043B2 (ru)
EP (1) EP3649156A1 (ru)
JP (1) JP2020525533A (ru)
KR (1) KR20200037250A (ru)
CN (2) CN111094350A (ru)
AU (1) AU2018297061B2 (ru)
BR (1) BR112020000228A2 (ru)
CA (1) CA3068933A1 (ru)
EA (1) EA202090005A1 (ru)
IL (1) IL271833A (ru)
PH (1) PH12020550010A1 (ru)
SG (1) SG11202000055PA (ru)
TW (1) TW201920275A (ru)
WO (1) WO2019009728A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117586403A (zh) 2016-10-11 2024-02-23 艾吉纳斯公司 抗lag-3抗体及其使用方法
EP3565841A1 (en) 2017-01-06 2019-11-13 Crescendo Biologics Limited Single domain antibodies to programmed cell death (pd-1)
GB201802573D0 (en) * 2018-02-16 2018-04-04 Crescendo Biologics Ltd Therapeutic molecules that bind to LAG3
CN112236456B (zh) * 2018-03-20 2023-12-22 上海药明生物技术有限公司 新型双特异性pd-1/lag-3抗体分子
EA202091871A1 (ru) * 2018-03-30 2021-06-22 Мерус Н.В. Поливалентное антитело
WO2020216348A1 (en) * 2019-04-26 2020-10-29 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific antibodies against pd-1 and lag-3
BR112021022405A2 (pt) 2019-05-09 2022-04-19 Merus Nv Domínios variantes para multimerização de proteínas e separação das mesmas
CA3176564A1 (en) 2020-05-27 2021-12-02 Agilent Technologies, Inc. Anti-human lag-3 antibodies and their use in immunohistochemistry (ihc)
CN112225813B (zh) * 2020-10-21 2021-12-21 北京智仁美博生物科技有限公司 针对破伤风毒素的抗体及其用途
EP4019633A1 (en) * 2020-12-23 2022-06-29 Technische Universität München Conditional cell connectors
EP4314062A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel pd-1 binding domains
CA3213682A1 (en) 2021-03-31 2022-10-06 Simon Edward PLYTE Multispecific binding moieties comprising novel pd-1 binding domains
EP4314061A1 (en) 2021-03-31 2024-02-07 Merus N.V. Novel multispecific antibodies
US20240101718A1 (en) * 2022-09-28 2024-03-28 Incyte Corporation Anti-pd-1/lag-3 bispecific antibodies and uses thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
ES2442615T5 (es) 2002-07-18 2023-03-16 Merus Nv Producción recombinante de mezclas de anticuerpos
WO2018157954A1 (de) 2017-03-01 2018-09-07 Fluorchemie Gmbh Frankfurt Neuartiges material, sowie dessen herstellung zur anwendung als speichermedium im sensitiven energiespeichersystem im niederen, mittleren und hochtemperaturbereich
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CA2721093A1 (en) 2008-04-11 2009-10-15 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
EP2556747B1 (en) 2008-06-27 2020-12-02 Merus N.V. Antibody producing transgenic mice
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US9181342B2 (en) 2008-09-12 2015-11-10 Isis Innovation Limited PD-1 specific antibodies and uses thereof
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
ES2893855T3 (es) 2011-08-11 2022-02-10 Ono Pharmaceutical Co Agente terapéutico para enfermedades autoinmunes que comprende agonista de PD-1
NZ630551A (en) 2012-04-20 2017-11-24 Merus Nv Methods and means for the production of ig-like molecules
NZ630563A (en) 2012-09-27 2017-04-28 Merus Nv Bispecific igg antibodies as t cell engagers
ME03558B (me) * 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
TWI693232B (zh) * 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016011069A1 (en) 2014-07-15 2016-01-21 The Board Of Trustees Of The Leland Stanford Junior University Medical uses of cd38 agonists (antibodies)
JO3663B1 (ar) * 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
KR20180019725A (ko) * 2015-06-23 2018-02-26 메모리얼 슬로안-케터링 캔서 센터 신규의 피디 1 면역 조절제
PT3328419T (pt) * 2015-07-30 2021-11-26 Macrogenics Inc Moléculas de ligação pd-1 e métodos de utilização
WO2017024515A1 (en) 2015-08-11 2017-02-16 Wuxi Biologics (Cayman) Inc. Novel anti-pd-1 antibodies
US11124569B2 (en) 2015-09-18 2021-09-21 Dana-Farber Cancer Institute, Inc. Methods of reducing liver PD-1-expressing CD8+ T cells using PD-1 Fc fusion proteins that bind Fc receptors
TWI756187B (zh) * 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
MX2018004988A (es) * 2015-10-23 2018-11-09 Merus Nv Moleculas de union que inhibe el crecimiento de cancer.
KR102317574B1 (ko) * 2015-11-18 2021-10-26 머크 샤프 앤드 돔 코포레이션 Pd1 및/또는 lag3 결합제
WO2018053405A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating immune disorders using pd-1 binding proteins
US10766958B2 (en) 2016-09-19 2020-09-08 Celgene Corporation Methods of treating vitiligo using PD-1 binding antibodies
JP7305538B2 (ja) * 2016-09-23 2023-07-10 メルス ナムローゼ フェンノートシャップ 細胞によって発現される生物活性を調節する結合分子
EP3389702A4 (en) 2017-02-22 2019-08-14 I-Mab ANTI-LAG-3 ANTIBODIES AND USES THEREOF
DE202017102208U1 (de) 2017-03-03 2018-03-07 Sarah Yanik Zusammensetzung, insbesondere für die Behandlung von Huf- und Klauenerkrankungen bei Tieren, und deren Herstellung
TW201920657A (zh) * 2017-07-06 2019-06-01 荷蘭商米樂斯股份有限公司 藉由細胞表現之調控生物活性的抗體
EP3649154A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
WO2020167122A1 (en) * 2019-02-14 2020-08-20 Merus N.V. Producing compositions comprising two or more antibodies.
EP4157354A1 (en) 2020-05-27 2023-04-05 Dana-Farber Cancer Institute, Inc. Bispecific molecules for selectively modulating t cells

Also Published As

Publication number Publication date
PH12020550010A1 (en) 2020-10-12
BR112020000228A2 (pt) 2020-07-14
EP3649156A1 (en) 2020-05-13
CA3068933A1 (en) 2019-01-10
JP2020525533A (ja) 2020-08-27
AU2018297061A1 (en) 2020-01-30
KR20200037250A (ko) 2020-04-08
IL271833A (en) 2020-02-27
CN117964759A (zh) 2024-05-03
WO2019009728A1 (en) 2019-01-10
WO2019009728A8 (en) 2020-01-09
CN111094350A (zh) 2020-05-01
AU2018297061B2 (en) 2021-05-06
TW201920275A (zh) 2019-06-01
US20200216540A1 (en) 2020-07-09
SG11202000055PA (en) 2020-02-27
US20230406932A1 (en) 2023-12-21
US11732043B2 (en) 2023-08-22

Similar Documents

Publication Publication Date Title
EA202090005A1 (ru) Антитела, модулирующие биологическую активность, проявляемую клеткой
EA202090004A1 (ru) Биспецифические антитела против pd-1 и против tim-3
CY1124232T1 (el) Συνδετικα μορια συνδεσης pd-l1 και lag-3
MX2022006447A (es) Anticuerpos anti-pd-1 novedosos.
SA518390862B1 (ar) Pd-l1 أجسام مضادة ضد
CO2018003973A2 (es) Proteínas de unión a pd-1 y métodos para usarlas
BR112018010410A8 (pt) método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1
MY201526A (en) Anti-trem2 antibodies and methods of use thereof
EA201990747A1 (ru) Способы лечения иммунных нарушений с применением белков, связывающих pd–1
EA201591467A1 (ru) Анти-lag-3 связывающие белки
PH12017502222A1 (en) Lag-3-binding molecules and methods of use thereof
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
CO2017007665A2 (es) Proteínas de unión a icos
MY181106A (en) Anti-lag3 antibodies and uses thereof
EA201900561A1 (ru) Конъюгаты циклодекстрин-белок-лекарственное средство
MX2020011828A (es) Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
EA201990530A1 (ru) Пути применения ингибиторов pd-1/pd-l1 и/или ингибиторов ctla-4 с биологическим средством, содержащим несколько цитокиновых компонентов, для лечения рака
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
EA201890320A1 (ru) Молекулы антител, которые связывают cd79
EA201992570A1 (ru) Составы на основе человеческих антител к rankl, а также способы их применения
EA201790439A1 (ru) Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
EA202091888A1 (ru) Вариабельные домены антител, нацеленные на рецептор nkg2d
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof
WO2015112895A3 (en) Antibody specific to staphylococcus aureus, therapeutic method and detection method using same
AU2021269176A8 (en) Single domain antibodies binding to SARS-CoV-2 spike protein